



(51) International Patent Classification:

C07K 16/28 (2006.01) G01N 33/554 (2006.01)  
C07K 16/46 (2006.01) A61K 39/395 (2006.01)  
G01N 15/14 (2024.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/US2024/023493

(22) International Filing Date:

06 April 2024 (06.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

|            |                                |    |
|------------|--------------------------------|----|
| 63/494,970 | 07 April 2023 (07.04.2023)     | US |
| 63/494,973 | 07 April 2023 (07.04.2023)     | US |
| 63/464,258 | 05 May 2023 (05.05.2023)       | US |
| 63/464,259 | 05 May 2023 (05.05.2023)       | US |
| 63/511,125 | 29 June 2023 (29.06.2023)      | US |
| 63/581,767 | 11 September 2023 (11.09.2023) | US |
| 63/591,594 | 19 October 2023 (19.10.2023)   | US |
| 63/605,804 | 04 December 2023 (04.12.2023)  | US |

(71) Applicant: CULLINAN ONCOLOGY, INC. [US/US];  
One Main Street, Suite 520, Cambridge, Massachusetts  
02142 (US).

(72) Inventors: MICHAELSON, Jennifer; One Main Street,  
Suite 520, Cambridge, Massachusetts 02142 (US).  
MEHTA, Naveen; One Main Street, Suite 520, Cambridge,  
Massachusetts 02142 (US). BAEUERLE, Patrick; One  
Main Street, Suite 520, Cambridge, Massachusetts 02142  
(US). MEETZE, Kristan; One Main Street, Suite 520,  
Cambridge, Massachusetts 02142 (US).

(74) Agent: TYSON, Malaika O.; McAndrews, Held & Malloy  
Ltd., 500 West Madison Street, 34th Floor, Chicago, Illinois  
60661 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS OF USE OF MULTI-SPECIFIC BINDING PROTEINS




FIG. 1B

(57) Abstract: Provided herein are anti-CD19 antibodies and multi-specific binding proteins that bind CD19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers including relapsing and/or refractory Non-Hodgkins Lymphoma, and cancers that express low levels of CD19.